Lefamulin was approved by the FDA in August 2019 for the treatment of CABP.
Allissa M. Long, PharmD and Kevin W. Chamberlin, PharmD, FASCP
Advertisement
Articles by Allissa M. Long, PharmD and Kevin W. Chamberlin, PharmD, FASCP
Advertisement
Latest Updated Articles
Lefamulin (Xenleta) for Community Acquired Bacterial PneumoniaPublished: January 21st 2020 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
General Awareness of PBM Practices Driving Optimism for Independent Pharmacies | NCPA 2025
2
How PBMs Legally Challenged Arkansas’ Pharmacy Ownership Law | NCPA 2025
3
COVID-19 Vaccination Benefits Patients With Systemic Lupus Erythematosus
4
FDA Releases Biosimilar Guidance Pushing to Streamline Development
5
